H. pylori Infection Raises LDL Cholesterol and Blood Sugar in 83,000-Person Study

A bacterium best known for causing peptic ulcers may be doing damage well beyond the stomach lining. A large-scale cross-sectional study published in BMC Infectious Diseases analyzed 83,054 adults at a health management center in central China and found that Helicobacter pylori infection is independently associated with elevated LDL cholesterol and higher fasting glucose levels. The findings add weight to the emerging picture of H. pylori as a systemic metabolic stressor, one whose effects on cardiovascular and blood sugar risk may be underappreciated in routine care.

H. pylori Independently Raises LDL Cholesterol and Fasting Glucose

Among the 83,054 participants screened between 2021 and 2025, 26.55% tested positive for H. pylori using the 13C Urea Breath Test, a well-validated non-invasive method. Infection rates peaked in the 50 to 54 age group, where prevalence reached 28.80%. After adjusting for age, sex, BMI, and a comprehensive biochemical profile, elevated LDL cholesterol emerged as the strongest independent correlate of H. pylori positivity, with an adjusted odds ratio of 1.34 (95% CI: 1.27 to 1.41). Fasting glucose was also significantly associated with infection, with each unit increase linked to an adjusted odds ratio of 1.04 (95% CI: 1.03 to 1.05). Total cholesterol appeared higher in infected individuals in unadjusted analyses, but that association weakened substantially once LDL was accounted for, suggesting LDL is the primary driver. This pattern is consistent with prior findings linking H. pylori to dyslipidemia in people with diabetes, where both total cholesterol and LDL levels tracked with infection status.

Cardiovascular Stakes for the Roughly One in Four Adults Infected

Even if the magnitude of each individual metabolic shift appears modest, the sheer scale of H. pylori infection makes these associations clinically meaningful. Global prevalence data show that while infection rates have declined from roughly 58% in the 1980s to around 43% between 2011 and 2022, hundreds of millions of people remain infected worldwide. An LDL odds ratio of 1.34 applied across that population could translate into a substantial number of people with metabolic profiles nudged in an atherogenic direction. Numerous studies have already noted a higher incidence of cardiovascular disease among H. pylori-infected individuals, with the hypothesis that systemic inflammation from the bacterium accelerates disease progression. The new Chinese cohort, one of the largest of its kind, strengthens the epidemiologic case that the stomach bug and the lipid panel are not independent concerns.

How an 83,054-Person Cohort Strengthened the Signal

Previous research on H. pylori and metabolic outcomes has been inconsistent, partly because smaller studies lacked the statistical power to separate H. pylori's effects from confounders like age, obesity, and pre-existing metabolic disease. The current study addressed this by recruiting a large, unselected group of health-check participants rather than patients already presenting with gastrointestinal complaints, reducing selection bias. Multivariable logistic regression allowed the researchers to adjust simultaneously for age, gender, BMI, and a wide biochemical panel. The result was a cleaner signal: LDL elevation and fasting glucose both held up as independent correlates after those adjustments, while other lipid markers like HDL and triglycerides did not show the same independent strength. The scale of the cohort, spanning four years of consecutive health screenings, also provided enough statistical power to detect effects as small as the per-unit fasting glucose association.

Open Questions About Mechanism and Causality

The most important caveat is the study's cross-sectional design: it can show that H. pylori infection and elevated LDL travel together, but it cannot prove one causes the other. The mechanisms proposed in the literature point toward plausible but not yet confirmed pathways. H. pylori infection is thought to drive metabolic dysregulation through immune modulation, systemic inflammation involving cytokines such as TNF-alpha and IL-6, oxidative stress, and disruption of lipid and glucose metabolism. Research has also pointed to chronic low-grade inflammation, gut dysbiosis, and insulin resistance as potential intermediaries linking H. pylori to dyslipidemia. The WHO classifies H. pylori as a Group I carcinogen, meaning its capacity to cause chronic mucosal inflammation is well established; whether that inflammation reliably propagates into measurable lipid shifts over time remains to be confirmed in prospective work. Sex-specific differences in metabolic response to infection also remain poorly characterized.

Whether Eradicating H. pylori Fixes the Metabolic Problem

The most actionable question the study raises is whether treating H. pylori would bring LDL and fasting glucose back down. Earlier work offers cautious optimism. One study found that successful anti-H. pylori therapy in patients with metabolic syndrome was accompanied by statistically significant improvements in carbohydrate and lipid metabolism alongside lower inflammatory markers, suggesting H. pylori eradication can improve metabolic outcomes. A Taiwanese cohort reported decreases in insulin resistance, triglycerides, and LDL after eradication. However, long-term effects of H. pylori eradication on metabolic syndrome appear mixed, with some studies finding no significant change in overall metabolic syndrome prevalence even when individual markers improved. The current authors call for longitudinal trials specifically designed to test whether eradication prevents cardiovascular events or slows the progression of glucose dysregulation over time. Until those trials are done, this study is best read as a signal, not a prescription: H. pylori infection is one more reason to pay attention to a bug that most people with it never knew they had.

Evidence rating

EMERGING — 82/100

Caveats:

• Cross-sectional design: this study shows association, not causation — it cannot confirm that H. pylori raises LDL-C or blood glucose, or that eradication would reverse these changes.
• Single-site, single-country cohort from central China; findings may not generalize to other populations.
• Funding was not disclosed by the authors, so potential conflicts of interest cannot be fully assessed.
• Proposed mechanisms (chronic inflammation, dysbiosis, insulin resistance) are plausible but not directly tested in this study.

Large retrospective cross-sectional study (n=83,054) using 13C Urea Breath Test for H. pylori status and multivariable logistic regression adjusted for age, sex, BMI, and a full biochemical panel. The design establishes association, not causation, and cannot determine whether H. pylori drives metabolic changes or whether shared risk factors explain the relationship. Findings are consistent with prior smaller studies but have not been independently replicated in a longitudinal or interventional design.

References

1. Meng Xie, Jing Xia, Qin Zeng, Dai-jin Ren, Yun Gong, Yin-hui Lu (2026). Association of Helicobacter pylori infection with elevated low-density lipoprotein cholesterol and fasting glucose: a large-scale analysis of 83,054 participants in central China. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-13767-9
2. Yuexi Li, Xiaoqin Liu, Qing Li, et al. (2025). Association of helicobacter pylori infection with lipid metabolism and 10-year cardiovascular risk in diabetes mellitus: A cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0319688
3. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis – PubMed. NIH. https://pubmed.ncbi.nlm.nih.gov/37090885/
4. Vlad Pădureanu, Dalia Dop, Daniel Cosmin Caragea, Dumitru Rădulescu, Rodica Pădureanu, Mircea-Cătălin Forțofoiu (2024). Cardiovascular and Neurological Diseases and Association with Helicobacter Pylori Infection—An Overview. Diagnostics. https://doi.org/10.3390/diagnostics14161781
5. Navid Maleki, Alireza Mohammadzadeh, Jalal Mardaneh, Hossein Pazoki, Elyas Nattagh-Eshtivani (2025). Helicobacter pylori infection and association with chronic diseases: A focus on cardiovascular disease, MASLD, and type 2 diabetes. Metabolism Open. https://doi.org/10.1016/j.metop.2025.100385
6. Yi Chen, Lingyan Shen, Ningning You, Jinshun Zhang (2025). Relationship between Helicobacter pylori infection and remnant cholesterol: the mediating role of insulin resistance and inflammation. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1684556
7. [Influence of Helicobacter pylori eradication on the metabolic syndrome components]. NIH. https://pubmed.ncbi.nlm.nih.gov/27045145/
8. Jaehyung Park, Nayoung Kim, Won Seok Kim, et al. (2022). Long-term Effects of the Eradication of Helicobacter pylori on Metabolic Parameters, Depending on Sex, in South Korea. Gut and Liver. https://doi.org/10.5009/gnl210588